We are live on ! Find out more
LPCN icon

Lipocine
LPCN

17 hedge funds and large institutions have $2.38M invested in Lipocine in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

3% less capital invested

Capital invested by funds: $2.44M → $2.38M (-$69.9K)

1.08% less ownership

Funds ownership: 10.18% → 9.1% (-1.1%)

6% less funds holding

Funds holding: 18 → 17 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
17
Holders Change
-1
Holders Change %
-5.56%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Geode Capital Management
Geode Capital Management
Massachusetts
+$16.5K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$12.7K
3
TRCT
Tower Research Capital (TRC)
New York
+$2.03K
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$330
5
Bank of America
Bank of America
North Carolina
+$30

Top Sellers

1
UBS Group
UBS Group
Switzerland
-$302K
2
Renaissance Technologies
Renaissance Technologies
New York
-$21.8K
3
Group One Trading
Group One Trading
Illinois
-$1.15K
4
CA
Clearstead Advisors
Ohio
-$333
5
T
Tidemark
California
-$265
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.08M – – –
BlackRock
2
BlackRock
New York
$436K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$280K +$16.5K +3,248 +6%
Renaissance Technologies
4
Renaissance Technologies
New York
$176K -$21.8K -4,300 -11%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$122K -$15 -3 -0%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$100K +$12.7K +2,500 +14%
State Street
7
State Street
Massachusetts
$90.9K – – –
Northern Trust
8
Northern Trust
Illinois
$64.2K – – –
Morgan Stanley
9
Morgan Stanley
New York
$12.9K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$7.15K +$2.03K +400 +38%
CSC
11
Caldwell Sutter Capital
California
$2.3K – – –
Osaic Holdings
12
Osaic Holdings
Arizona
$1.11K – – –
Group One Trading
13
Group One Trading
Illinois
$961 -$1.15K -226 -53%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$317 +$330 +65 New
Bank of America
15
Bank of America
North Carolina
$303 +$30 +6 +11%
JP Morgan Chase
16
JP Morgan Chase
New York
$59 – – –
UBS Group
17
UBS Group
Switzerland
$15 -$302K -59,410 -100%
CA
18
Clearstead Advisors
Ohio
– -$333 -74 Closed
T
19
Tidemark
California
– -$265 -59 Closed

LPCN Hedge Fund Activity: Q4 2024 in Review

17 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2024, worth a combined $2.38M — down 2.9% from $2.44M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LPCN and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $16.5K. The largest seller was UBS Group, cutting an estimated $302K.

  • 17 institutional investors held Lipocine (LPCN) as of Q4 2024, down from 18 in Q3 2024.
  • Funds reported $2.38M of Lipocine stock for Q4 2024, down 2.9% quarter-over-quarter.
  • 1 fund opened new Lipocine positions in Q4 2024 and 2 closed out, a net change of -1 holder.
  • The largest Lipocine buyer in Q4 2024 was Geode Capital Management, an estimated $16.5K added.
  • The largest Lipocine seller in Q4 2024 was UBS Group, an estimated $302K sold.

Based on aggregated 13F filings for Q4 2024.